Search Results

Syntron's QuikPac II One Step Benzodiazepine assay is a rapid, qualitative, competitive binding immunoassay for the determination of Benzodiazepine in urine at the cutoff level of 200 ng/ml. The test provides only preliminary data which should be confirmed by other methods such as gas chromatography/mass spectrophotometry (GC/MS). Clinical considerations and professional judgment should be applied to any drug of abuse test result, particularly when preliminary positive results are indicated6. Syntron's QuikPac II One Step Benzodiazepine Test is not intended to monitor drug levels, but only to screen urines for the presence of Benzodiazepine and its metabolites.

Syntron's QuikPac II One Step Benzodiazepine Test consists of a chromatographic absorbent device in which the drug or drug metabolites in the sample compete with a drug conjugate immobilized on a porous membrane support for the limited antibody sites. As the test sample flows through the absorbent device, the labeled antibody-dye conjugate binds to the free drug in the specimen forming an antibody:antigen complex. This complex competes with immobilized antigen conjugate in the positive reaction zone and will not produce a magenta color band when the drug is above the detection level of 200 ng/ml. Unbound dye conjugate binds to the reagent in the control zone, producing a magenta color band, demonstrating that the reagents and device are functioning correctly.

Here's an analysis of the provided text, focusing on the acceptance criteria and the study details:

1. Table of Acceptance Criteria and Reported Device Performance

Note on Acceptance Criteria: The document does not explicitly state pre-defined acceptance criteria in terms of specific thresholds for accuracy, sensitivity, or specificity that the device had to meet. Instead, it presents the results of studies and implies that these results were deemed acceptable for substantial equivalence. The predicate device (Syva EMIT® II) is used as a comparator, and GC/MS is used as the gold standard for confirmation.

2. Sample Sizes and Data Provenance

• Test Set Sample Sizes:
  • In-house testing: Not explicitly stated, but the performance metrics (1.000 agreement for positive, 0.9740 for negative, 98.54% accuracy) were derived from testing against "samples documented to be positive by GC/MS(200)". The number of false positives (2) is mentioned for the in-house testing.
  • Clinical Trial: 303 samples.
• Data Provenance: The document does not explicitly state the country of origin.
  • In-house testing: Performed by Syntron Bioresearch, Inc. (the sponsor).
  • Clinical Trial: The samples were presumably collected as part of a clinical trial, implying prospective data collection, though not explicitly stated as such. It mentions "The testing performed by both the sponsor and the Clinical Trial site." This suggests some clinical trial data.

3. Number of Experts and Qualifications for Ground Truth

• Number of Experts: Not applicable. The ground truth was established by laboratory methods, not by human expert interpretation of images or other subjective data.
• Qualifications of Experts: Not applicable.

4. Adjudication Method for the Test Set

• Adjudication Method: Not applicable. The "ground truth" was established through Gas Chromatography/Mass Spectrophotometry (GC/MS) at a specific cutoff (200 ng/ml), which is a definitive laboratory technique, not requiring human adjudication of differing interpretations.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

• MRMC Study: No. This is a diagnostic device for substance detection in urine, not an imaging device that requires human interpretation or assistance. Therefore, an MRMC study is not relevant.
• Effect size of human readers with/without AI: Not applicable.

6. Standalone (Algorithm Only) Performance

• Standalone Performance: Yes. The "QuikPac II One Step Benzodiazepine Test" is a standalone device. Its performance metrics (agreement, accuracy) were measured directly against a comparator (EMIT® II) and a confirmatory gold standard (GC/MS). The results reported are the standalone performance of the device. There is no human-in-the-loop component for the device's operation or interpretation of its direct output (color band).

7. Type of Ground Truth Used

• Type of Ground Truth: Chemical analysis and confirmed presence/absence of benzodiazepines. Specifically, Gas Chromatography/Mass Spectrophotometry (GC/MS) at a cutoff level of 200 ng/ml was used as the definitive method to establish the true presence or absence of the drug and its metabolites.

8. Sample Size for the Training Set

• Training Set Sample Size: The document does not provide information about a separate "training set" or its size. This type of diagnostic device (immunoassay) is typically developed and validated using known samples rather than machine learning algorithms requiring a distinct training phase. The "in-house testing" and "clinical trial" refer to the validation/testing of the final device.

9. How Ground Truth for the Training Set Was Established

• Ground Truth for Training Set: Not applicable, as a distinct training set is not mentioned for this type of device. The development process likely involved using samples of known benzodiazepine concentration (established by methods like GC/MS) to calibrate the assay's sensitivity and specificity, but these wouldn't typically be referred to as a "training set" in the context of AI/ML. The "in-house testing" used "samples documented to be positive by GC/MS(200)."

Ask a specific question about this device